No 50% Wednesday Discount Confirmed for AMC Theatres

Published 5 hours agoAMC

No 50% Wednesday Discount Confirmed for AMC Theatres

As of May 12, 2025, there is no information available indicating that AMC Theatres plans to slash ticket prices by 50% on Wednesdays. While such a drastic discount would likely draw in more moviegoers midweek, AMC currently has no verified announcements pointing to this strategy.

Currently, AMC Theatres provides several other promotions aimed at attracting cinema enthusiasts. For instance, 'Discount Tuesdays' offer AMC Stubs members significant savings on tickets. Another popular deal is the 'Matinee Pricing', where moviegoers can snag a 25% discount on tickets before 4 p.m. every day. Additionally, AMC has run a 'Summer Movie Camp' in past years featuring reduced prices for family-friendly screenings on select days, as noted by publications including abc7chicago.com.

For those interested in AMC's current promotions and offerings, visiting their official website or reaching out to local AMC locations directly is recommended. These sources ensure that cinema lovers have the most up-to-date information on any discounts or special programs available.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Coherus BioSciences Targets $200 Million Market for LOQTORZI in NPC

Coherus BioSciences Targets $200 Million Market for LOQTORZI in NPC

13 minutes agoCHRS

Coherus BioSciences has identified a substantial market opportunity for LOQTORZI, setting its sights on a $150 million to $200 million target in the nasopharyngeal carcinoma (NPC) arena. The treatment garnered FDA approval in January 2024, making it the first approved therapy for recurrent, locally advanced, or metastatic NPC, and was launched across all lines of therapy. Several developments have aided LOQTORZI’s growth trajectory. In November 2024, the National Comprehensive Cancer Network updated its guidelines to bestow LOQTORZI with Preferred status for both first-line and second-line treatment settings. Additionally, the drug saw a significant boost in sales, reporting $7.5 million in net product sales for the fourth quarter of 2024—a 29% increase from the prior quarter—with annual sales reaching $19.1 million, according to GlobeNewswire. Coherus continues to fortify its position in the market through strategic collaborations, including partnerships with Junshi Biosciences and INOVIO Pharmaceuticals. These alliances are pivotal in expanding LOQTORZI’s therapeutic applications and market footprint. Concurrently, Coherus is enhancing its oncology pipeline with innovative treatments such as casdozokitug and CHS-114, further positioning the company for future growth in the oncology sector.

FiscalNote Reaffirms Revenue Outlook Amid Strategic Initiatives

FiscalNote Reaffirms Revenue Outlook Amid Strategic Initiatives

28 minutes agoNOTE

FiscalNote has confidently reaffirmed its revenue outlook for 2025 while intensifying its focus on migration and debt reduction strategies. In the fourth quarter of 2024, the company exceeded its previous guidance, reporting total revenues of $29.5 million and an adjusted EBITDA of $3.3 million. This achievement marks the sixth consecutive quarter of positive adjusted EBITDA, highlighting a 10% improvement compared to the previous year. Efforts to streamline operations have also been fruitful, with a significant 44% reduction in senior debt over the past year. The expected closing of a $40 million deal to sell Oxford Analytica and Dragonfly Intelligence to Dow Jones by March 2025 will further enhance FiscalNote's balance sheet. Reuters noted that these moves are part of a broader strategy to divest non-core assets and strengthen the company's focus on its core policy platform. Looking ahead, FiscalNote is in the process of migrating its users to the newly launched AI-driven PolicyNote platform, which aims to boost customer engagement and drive revenue growth in the years to come. For 2025, the company projects revenues between $94 million and $100 million, alongside an anticipated adjusted EBITDA ranging from $10 million to $12 million. These strategic initiatives are a testament to FiscalNote's dedication to financial robustness and streamlining its operations towards core policy solutions.

Microvast Reports Record Revenue and Sets Ambitious Targets for 2025

Microvast Reports Record Revenue and Sets Ambitious Targets for 2025

43 minutes agoMVST

Microvast Holdings, Inc. has experienced a noteworthy year, closing 2024 with an impressive revenue of $379.8 million, marking a 23.9% increase from the previous year. Despite increasing their gross margin to 31.5% from 18.7% in 2023, the company reported a net loss of $82.3 million in the fourth quarter of 2024, up from the $24.6 million loss during the same period in 2023. Looking ahead, Microvast has set its sights on a revenue target of $450 million to $475 million for 2025, which represents an 18% to 25% year-over-year growth. The company's regional performance is particularly strong in the EMEA region, where it saw a remarkable 212% increase in sales in the third quarter of 2024, according to Investing.com. There is also an expectation of an 80% revenue growth for the EMEA region in the fourth quarter. The company is strategically expanding its operations and production capabilities at its Huzhou Phase 3.2 facility to meet growing demand. Microvast is also working on new product developments, such as the ME6 ESS container solution and silicon-based cells, to position itself strongly in the evolving commercial vehicle markets as more OEMs electrify their product lines. These efforts underline Microvast's focus on growth and operational efficiency.

NuScale Power Eyes First SMR Customer Order by 2025

NuScale Power Eyes First SMR Customer Order by 2025

NuScale Power is making significant strides to secure its first Small Modular Reactor (SMR) customer by 2025. The company is in advanced discussions with various technology firms, industrial companies, utilities, and government bodies aiming to deploy its SMR technology. These engagements mark a crucial step in potentially transforming clean energy solutions. NuScale is particularly focused on reaching agreements with high-impact sectors, including data centers and manufacturers seeking sustainable electricity solutions. Partnerships and strategic moves have been at the forefront of NuScale’s recent initiatives. Collaborating with ENTRA1 Energy, the company is developing SMR-powered facilities in Ohio and Pennsylvania, anticipated to deliver close to 2GW of clean energy tailored for data centers. Additionally, NuScale is advancing its supply chain by placing long-lead material orders with Doosan Enerbility. These efforts are complemented by regulatory advancements, as NuScale progresses towards mid-2025 approval of its Standard Design Approval application with the U.S. Nuclear Regulatory Commission. Amid these developments, market interest in NuScale's SMR technology is growing, particularly among hyperscale data center operators. Reuters reported an uptick in demand from companies wanting emissions-free and reliable power solutions. As NuScale pursues its goal of the first customer order by 2025, its current stock price is $17.79, with a slight change of $1.03, and sees significant intraday trading activity.